Distressed asset opportun Recent Chapter 11 proceedings and asset sales indicate Eiger BioPharmaceuticals is actively restructuring. This creates a potential sales window for partners or acquirers with a focus on divestitures, royalty arrangements, or contracted research collaborations to capitalize on remaining programs such as avexitide.

Avexitide value Avexitide is a first-in-class GLP-1 antagonist with FDA Breakthrough Therapy designation for PBH and congenital hyperinsulinism. This unique asset may attract interest from specialty pharma, CROs for development support, or manufacturing partners capable of supporting late-stage progression or commercialization in niche metabolic indications.

Strategic collaboration The company has engaged in asset divestitures and has ongoing Phase II and other exploratory programs. There is potential for strategic partnerships, licensing, or co-development deals with firms seeking rare disease pipelines, particularly those with metabolic or hepatic indications.

Capital efficiency With modest revenue and a relatively small team, Eiger may be pursuing lean operations or capital-friendly restructurings. This creates opportunities for cost-effective CRO services, clinical development support, regulatory consulting, or platform technologies aimed at accelerating time-to-value for rare-disease programs.

Market narrative The selling of assets and focus on rare metabolic disease therapies positions Eiger as a potential partner for companies looking to broaden their rare-disease portfolios through acquisitions, licensing, or supply-chain partnerships, especially with players active in PBH, HI, or related metabolic conditions.